MOONLAKE IMMUNOTHERAPEUTICS

NASDAQ: MLTX (MoonLake Immunotherapeutics)

Kemas kini terakhir: 23 jam lalu

11.74

-0.76 (-6.08%)

Penutupan Terdahulu 12.50
Jumlah Dagangan 778,485
Harga / Buku (P/B) 2.79
Julat 52 Minggu
9.46 (-19%) — 23.29 (98%)
EPS Cair (TTM) -2.30
Jumlah Hutang/Ekuiti (D/E MRQ) 18.32%
Nisbah Semasa (MRQ) 21.11
Aliran Tunai Operasi (OCF TTM) -139.78 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -102.40 M
Pulangan Atas Aset (ROA TTM) -19.85%
Pulangan Atas Ekuiti (ROE TTM) -30.64%

AISkor Stockmoo

-0.2
Nilai 30% -0.5
Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info NA
Penilaian Relatif info NA
Pertumbuhan Tersirat info NA
Sejarah Penilaian info NA
Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info
Pulangan di bawah kos modalnya. Pulangan atas modal meningkat. info
Masa 30% -3.0
Daripada analisis teknikal AI kami terhadap carta. info NA
Aliran menurun sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info
Corak Lilin info NA
Aliran bagi Tempoh Pegangan Anda info NA
Sentimen 20% 0.3
Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info
Berita terkini kebanyakannya positif. info
Wang Pintar 20% 3.6
Aktiviti Orang Dalam info NA
Institusi bersih +19.19% daripada saham dalam pemfailan 13F terkini: 103 pemegang menambah, 83 mengurang (suku berakhir 30 Sep 2026). info
Kedudukan jual singkat -23.4% dari 31 Aug hingga 30 Oct 2026, 2.9 hari untuk tutup (FINRA). info
Keadaan pasaran dan sektor lemah.
Persekitaran pasaran berhati-hati. info
Sektor ketinggalan berbanding pasaran.
Tonggak-tonggak tidak sependapat, jadi skor dilemahkan.
Tidak dikira dalam skor
Harga rendah berbanding purata 52 minggunya. Naik dalam tempoh 5 tahun. info
Momentum jangka pendek meningkat. info
Harga di antara sokongan dan rintangan. info
Skor Akhir -0.24

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menaik
Biotechnology (Global) Bercampur Menaik
Stok MoonLake Immunotherapeutics Bercampur Menaik

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
MLTX - - - 2.79
TRML 1 B - - 4.76
TECH - 0.44% - 5.28
VKTX - - - 6.33
VSTM - - - 76.50
CRMD - - - 0.800

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Core
% Dimiliki oleh Orang Dalam 15.34%
% Dimiliki oleh Institusi 96.70%

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

Institusi

Pemilikan institusi: 94.73%

Kedudukan Pemegang Saham
Bertambah 103 21,066,532
Berkurang 83 10,045,773
Baharu 38 8,512,207
Dijual habis 31 3,220,864

Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.

Kedudukan Jual Singkat

Penyelesaian Saham Hari untuk tutup
30 Oct 2026 5,473,842 2.9
15 Oct 2026 7,833,997 4.1
30 Sep 2026 8,048,665 4.2
15 Sep 2026 8,947,906 6.1
31 Aug 2026 7,144,513 6.7
14 Aug 2026 6,819,147 4.2

Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.

2 Positif 1 Negatif 2 Neutral
Tarikh Jenis Butiran
12 Nov 2026 Yahoo Finance MoonLake Immunotherapeutics (MLTX) Stock Could Be Above Fair Value On Book Value Concerns
MoonLake Immunotherapeutics has seen sharp swings over the past few years, and the latest share price level puts fresh focus on a simple question for you as an investor: Is the current valuation of MoonLake Immunotherapeutics stock meaningfully backed up by the strength of its balance sheet and its…
11 Nov 2026 Yahoo Finance MLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug Filing
MoonLake is developing Sonelokimab primarily for hidradenitis suppurativa (HS), a chronic inflammatory skin condition with limited effective treatments.
10 Nov 2026 Yahoo Finance Is MoonLake Immunotherapeutics (MLTX) Cheap On Earnings Losses And Sonelokimab Milestones?
MoonLake Immunotherapeutics (MLTX) just posted third quarter 2026 results, reporting a net loss of US$79.55 million and a diluted loss per share of US$0.93. The company also reaffirmed its focus on sonelokimab regulatory milestones. The latest earnings update landed after a sharp pullback, with…
09 Nov 2026 Yahoo Finance MoonLake Immunotherapeutics Stock In Focus After Quarterly Loss Update
MoonLake Immunotherapeutics reported third quarter 2026 results with a net loss of US$79.55 million and basic and diluted loss per share of US$0.93, and a nine month 2026 net loss of US$211.06 million with basic and diluted loss per share of US$2.74. The narrower quarterly loss per share compared…
04 Nov 2026 Yahoo Finance MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update
Biologics License Application for sonelokimab submitted to the U.S. Food and Drug Administration for the treatment of adults and adolescents with moderate-to-severe hidradenitis suppurativa, marking an important step towards potential U.S. approval and commercializationPositive Week 16 results from…
25 Oct 2026 Yahoo Finance MoonLake Immunotherapeutics (MLTX) Rides HS Narrative Following Rebound As Undervalued View Holds
Recent Performance Snapshot MoonLake Immunotherapeutics (MLTX) has drawn fresh attention after recent trading saw the share price close at $11.85. Performance has been mixed across timeframes and marked by sharp moves over the past 3 months. That recent jump in MoonLake Immunotherapeutics, with a…
24 Oct 2026 Yahoo Finance MoonLake Immunotherapeutics (MLTX) Stock Trades Above Fair Value On Balance Sheet Questions
MoonLake Immunotherapeutics has seen sharp swings in its share price in recent years, which puts fresh focus on what investors are really paying for on the balance sheet. With the stock last closing at US$11.85, the live question is how that market tag lines up with the company’s book value. The…
22 Oct 2026 Yahoo Finance AbbVie Slips Behind Rivals as Lutikizumab Hits 31.4% Response in HS Trial
Key TakeawaysAbbVie’s lutikizumab met its Phase 3 goal in hidradenitis suppurativa, with 31. 4% of patients reaching HiSCR75 at Week 16 versus 23…
22 Oct 2026 Yahoo Finance MoonLake Soars 18% as Rival AbbVie’s Skin Disease Trial Data “Underwhelms”
Key TakeawaysMoonLake shares jumped 18% today after AbbVie reported Phase 3 results for a rival hidradenitis suppurativa drug. AbbVie’s lutikizumab beat placebo by 8 percentage points on its main goal, a result RBC Capital called underwhelming.
16 Oct 2026 Yahoo Finance MoonLake Immunotherapeutics Makes Case for Sonelokimab Approval, RBC Says
MoonLake Immunotherapeutics (MLTX) made a "reasonably solid" case for the approvability of sonelokim…
05 Oct 2026 Yahoo Finance MoonLake Immunotherapeutics Could Win FDA Approval for Sonelokimab by Year-End 2027, Wedbush Says
MoonLake Immunotherapeutics (MLTX) could receive US Food and Drug Administration approval for sonelo…
21 Sep 2026 Yahoo Finance Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight
The launch of emerging therapies such as ILUMYA/ILUMETRI (tildrakizumab-asmn; Sun Pharma), Izokibep (Affibody Medical), ICOTYDE (icotrokinra; Johnson & Johnson), Zasocitinib (TAK-279; Takeda), Sonelokimab (MoonLake Immunotherapeutics), Vunakizumab (Suzhou Suncadia), SPY 072 (Spyre Therapeutics)…
11 Sep 2026 Yahoo Finance MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock more than 75% below its 52-week high.
Papar semua

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda